［1］ FORNER A,LLOVET JM,BRUIX J.Hepatocellular carcinoma［J］.Lancet,2012,379(9822):1245-1255.
［2］ CHEN W,ZHENG R,BAADE PD,et al.Cancer statistics in China,2015［J］.CA Cancer J Clin,2016,66(2):115-132.
［3］ WHO.Global battle against cancer won't be won with treatment alone-effective prevention measures urgently needed to prevent cancer crisis［J］.Cent Eur J Public Health,2014,22(1):23-28.
［4］ European Association for the Study of the Liver.Electronic address:easloffice@easloffice.eu,European Association for the Study of the Liver.EASL Clinical Practice Guidelines:Management of hepatocellular carcinoma［J］.J Hepatol,2018,69(1):182-236.
［5］ ZHU J,YIN T,XU Y,et al.Therapeutics for advanced hepatocellular carcinoma:Recent advances,current dilemma,and future directions［J/OL］.J Cell Physiol,2019.https://doi.org/10.1002/jcp.28048.
［6］ FESSLER MB.The challenges and promise of targeting the Liver X Receptors for treatment of inflammatory disease［J］.Pharmacol Ther,2018,16(181):1-12.
［7］ BOBIN-DUBIGEON C,CHAUVIN A,BRILLAUD-MEFLAH V,et al.Liver X receptor (LXR)-regulated genes of cholesterol trafficking and breast cancer severity［J］.Anticancer Res,2017,37(10):5495-5498.
［8］ VENTECLEF N,FERRE P.Liver X receptor:from metabolism to cancer［J］.Biochem J,2014,459(2):e1-3.
［9］ TORRES-LUQUIS O,MADDEN K,N'DRI NM,et al.LXR/RXR pathway signaling associated with triple-negative breast cancer in African American women［J］.Breast Cancer (Dove Med Press),2019,11:1-12.
［10］ PATTANAYAK SP,BOSE P,SUNITA P,et al.Bergapten inhibits liver carcinogenesis by modulating LXR/PI3K/Akt and IDOL/LDLR pathways［J］.Biomed Pharmacother,2018,108:297-308.
［11］ JU X,HUANG P,CHEN M,et al.Liver X receptors as potential targets for cancer therapeutics［J］.Oncol Lett,2017,14(6):7676-7680.
［12］ MCDONNELL DP,PARK S,GOULET MT,et al.Obesity,cholesterol metabolism,and breast cancer pathogenesis［J］.Cancer Res,2014,74(18):4976-4982.
［13］ LIN CY,VEDIN LL,STEFFENSEN KR.The emerging roles of liver X receptors and their ligands in cancer［J］.Expert Opin Ther Targets,2016,20(1):61-71.
［14］ WILLY PJ,UMESONO K,ONG ES,et al.LXR,a nuclear receptor that defines a distinct retinoid response pathway［J］.Genes Dev,1995,9(9):1033-1045.
［15］ LANGE PT,SCHORL C,SAHOO D,et al.Liver X receptors suppress activity of cholesterol and fatty acid synthesis pathways to oppose gammaherpesvirus replication［J］.MBio,2018,9(4):e01115-01118.
［16］ IM SS,OSBORNE TF.Liver x receptors in atherosclerosis and inflammation［J］.Circ Res,2011,108(8):996-1001.
［17］ WOJCICKA G,JAMROZ-WISNIEWSKA A,HOROSZEWICZ K,et al.Liver X receptors (LXRs).Part I:structure,function,regulation of activity,and role in lipid metabolism［J］.Postepy Hig Med Dosw (Online),2007,61:736-759.
［18］ JANOWSKI BA,GROGAN MJ,JONES SA,et al.Structural requirements of ligands for the oxysterol liver X receptors LXRalpha and LXRbeta［J］.Proc Natl Acad Sci USA,1999,96(1):266-271.
［19］ JANOWSKI BA,WILLY PJ,DEVI TR,et al.An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha［J］.Nature,1996,383(6602):728-731.
［20］ LEHMANN JM,KLIEWER SA,MOORE LB,et al.Activation of the nuclear receptor LXR by oxysterols defines a new hormone response pathway［J］.J Biol Chem,1997,272(6):3137-3140.
［21］ CHENG TJ,LIN SW,CHEN CW,et al.Arsenic trioxide suppresses liver X receptor β and enhances cholesteryl ester transfer protein expression without affecting the liver X receptor α in HepG2 cells［J］.Chem Biol Interact,2016,25(258):288-296.
［22］ FORBES KP,KOURANOVA E,TINKER D,et al.Creation and preliminary characterization of pregnane X receptor and constitutive androstane receptor knockout rats［J］.Drug Metab Dispos,2017,45(10):1068-1076.
［23］ CHEN QJ,SHI Y,SHI JF,et al.Liver X receptors agonist T0901317 downregulates matrix metalloproteinase-9 expression in non-small-cell lung cancer by repressing nuclear factor-κB［J］.Anticancer Drugs,2017,28(9):952-958.
［24］ KATZ A,UDATA C,OTT E,et al.Safety,pharmacokinetics,and pharmacodynamics of single doses of LXR-623,a novel liver X-receptor agonist,in healthy participants［J］.J Clin Pharmacol,2009,49(6):643-649.
［25］ YASUDA T,GRILLOT D,BILLHEIMER JT,et al.Tissue-specific liver X receptor activation promotes macrophage reverse cholesterol transport in vivo［J］.Arterioscler Thromb Vasc Biol,2010,30(4):781-786.
［26］ KANEKO E,MATSUDA M,YAMADA Y,et al.Induction of intestinal ATP-binding cassette transporters by a phytosterol-derived liver X receptor agonist［J］.J Biol Chem,2003,278(38):36091-36098.
［27］ WALCHER D,KüMMEL A,KEHRLE B,et al.LXR activation reduces proinflammatory cytokine expression in human CD4-positive lymphocytes［J］.Arterioscler Thromb Vasc Biol,2006,26(5):1022-1028.
［28］ CHANG L,ZHANG Z,LI W,et al.Liver-X-receptor activator prevents homocysteine-induced production of IgG antibodies from murine B lymphocytes via the ROS-NF-kappaB pathway［J］.Biochem Biophys Res Commun,2007,357(3):772-778.
［29］ HEINE G,DAHTEN A,HILT K,et al.Liver X receptors control IgE expression in B cells［J］.J Immunol,2009,182(9):5276-5282.
［30］ ZELCER N,TONTONOZ P.Liver X receptors as integrators of metabolic and inflammatory signaling［J］.J Clin Invest,2006,116(3):607-614.
［31］ JOSEPH SB,BRADLEY MN,CASTRILLO A,et al.LXR-dependent gene expression is important for macrophage survival and the innate immune response［J］.Cell,2004,119(2):299-309.
［32］ 熊志勇,吴珏堃,梁豪.基于癌症基因信息数据库分析载脂蛋白F在肿瘤中生物学意义［J］.中华实验外科杂志,2018,35(3):570.
XIONG ZY,WU JK,LIANG H.Analysis of the biological significance of apolipoprotein F in cancer based on the cancer genome atlas［J］.Chin J Exp Surg,2018,35(3):570.
［33］ SU W,PENG J,LI S,et al.Liver X receptor α induces 17β-hydroxysteroid dehydrogenase-13 expression through SREBP-1c［J］.Am J Physiol Endocrinol Metab,2017,312(4):E357-E367.
［34］ POMMIER AJ,ALVES G,VIENNOIS E,et al.Liver X Receptor activation downregulates AKT survival signaling in lipid rafts and induces apoptosis of prostate cancer cells［J］.Oncogene,2010,29(18):2712-2723.
［35］ GONG H,GUO P,ZHAI Y,et al.Estrogen deprivation and inhibition of breast cancer growth in vivo through activation of the orphan nuclear receptor liver X receptor［J］.Mol Endocrinol,2007,21(8):1781-1790.
［36］ KANEKO T,KANNO C,ICHIKAWA-TOMIKAWA N,et al.Liver X receptor reduces proliferation of human oral cancer cells by promoting cholesterol efflux via up-regulation of ABCA1 expression［J］.Oncotarget,2015,6(32):33345-33357.
［37］ CANDELARIA NR,ADDANKI S,ZHENG J,et al.Antiproliferative effects and mechanisms of liver X receptor ligands in pancreatic ductal adenocarcinoma cells［J］.PLoS One,2014,9(9):e106289.
［38］ UNO S,ENDO K,JEONG Y,et al.Suppression of beta-catenin signaling by liver X receptor ligands［J］.Biochem Pharmacol,2009,77(2):186-195.
［39］ 谭湘洲,王然,文俏程,等.肝X受体激动剂GW3965对人结肠癌细胞奥沙利铂耐药的逆转作用及机制［J］.中国普通外科杂志,2017,26(10):1258-1264.
TAN XZ,WANG R,WEN QC,et al.Reversal effect of liver X receptor agonist GW3965 on oxaliplatin resistance in human colon cancer cells and its mechanism ［J］.Chinese Journal of General Surgery,2017,26(10):1258-1264.
［40］ LEMPINEN M,LYYTINEN I,NORDIN A,et al.Prognostic value of serum MMP-8,-9 and TIMP-1 in patients with hepatocellular carcinoma［J］.Ann Med,2013,45(7):482-487.
［41］ XIONG T,LI Z,HUANG X,et al.TO901317 inhibits the development of hepatocellular carcinoma by LXRα/Glut1 decreasing glycometabolism［J］.Am J Physiol Gastrointest Liver Physiol,2019,316(5):G598-G607.
［42］ LONG H,GUO X,QIAO S,et al.Tumor LXR Expression is a prognostic marker for patients with hepatocellular carcinoma［J］.Pathol Oncol Res,2018,24(2):339-344.
［43］ MOREN A,BELLOMO C,TSUBAKIHARA Y,et al.LXRα limits TGFβ-dependent hepatocellular carcinoma associated fibroblast differentiation［J］.Oncogenesis,2019,8(6):36.
［44］ YOUN M,WANG N,LAVASSEUR C,et al.Loss of Forkhead box M1 promotes erythropoiesis through increased proliferation of erythroid progenitors［J］.Haematologica,2017,102(5):826-834.
［45］ SUN HC,LI M,LU JL,et al.Overexpression of Forkhead box M1 protein associates with aggressive tumor features and poor prognosis of hepatocellular carcinoma［J］.Oncol Rep,2011,25(6):1533-1539.
［46］ HU C,LIU D,ZHANG Y,et al.LXRalpha-mediated downregulation of FOXM1 suppresses the proliferation of hepatocellular carcinoma cells［J］.Oncogene,2014,33(22):2888-2897.
［47］ 何靖炀,刘秋英,魏玲,等.BORIS通过表观修饰对人肝癌细胞SOCS3表达的调控［J］.四川大学学报（医学版）,2018,49(1):1-7.
HE JY,LIU QY,WEI L,et al.BORIS regulates SOCS3 expression through epigenetic mechanisms in human hepatocellular carcinoma cells ［J］.Sichuan Univ(Med Sci Edi),2018,49(1):1-7.
［48］ OGATA H,KOBAYASHI T,CHINEN T,et al.Deletion of the SOCS3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis［J］.Gastroenterology,2006,131(1):179-193.
［49］ XIONG H,ZHANG Y,CHEN S,et al.Induction of SOCS3 by liver X receptor suppresses the proliferation of hepatocellular carcinoma cells［J］.Oncotarget,2017,8(38):64083-64094.